Skip to main content

Table 5 Odds ratios (OR) and 95 % CI for association of serum folate concentration with prostate cancer and according to folate metabolic pathway gene polymorphisms

From: Complex interaction between serum folate levels and genetic polymorphisms in folate pathway genes: biomarkers of prostate cancer aggressiveness

 

Cases/controls

Adjusteda OR (95 % CI) tertiles of serum folate (nmol/L)

p intϕ

1 (2.9–7.4)

2 (7.5–11.0)

3 (11.1–24.0)

MTHFR A1298C

 

 

 

 

 

Total prostate cancerb

199/202

 

 

 

 

 AA

137/151

(ref.)

3.82 (1.68–8.67)

6.33 (2.90–13.85)

0.257

 AC + CC

62/51

2.09 (0.66–6.68)

2.49 (0.78–7.97)

11.31 (4.22–30.37)

 

MTHFR C677T

Total prostate cancerb

202/206

 

 

 

 

 CC

157/164

(ref.)

2.72 (1.21–6.12)

6.75 (3.19–14.27)

0.83

 CT + TT

45/42

1.07 (0.33–3.45)

3.48 (1.25–9.70)

5.74 (2.01–16.33)

 

MTRR A66G

Total prostate cancerb

195/203

 

 

 

 

 AA

111/120

(ref.)

3.40 (1.38–8.36)

4.39 (1.85–10.40)

0.143

 AG + GG

84/83

0.72 (0.23–2.28)

2.06 (0.76–5.64)

7.86 (3.20–19.35)

 

MTR A2756G

Total prostate cancer b

199/205

 

 

 

 

 AA

97/99

(ref.)

3.33 (1.22–9.09)

5.01 (1.99–12.60)

0.628

 AG +GG

102/106

0.93 (0.32–2.72)

2.68 (1.02–6.99)

6.78 (2.69–17.07)

 
  1. aModels adjusted for age and BMI as continuous, education (primary or less, secondary or higher), family history of prostate cancer (no/yes), vitamin use (no/yes), and smoking (non-smoker, ex-smoker, current smoker)
  2. b7 cases—Gleason scores unknown
  3. ϕ  p value for the interaction